Clinical Trials Browser

Phase 1/2 × Interventional × alectinib × Clear all

NCT05713006 2026-04-08

Alectinib Pharmacokinetic in Patients With NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05987644 2026-04-08

DURABLE

Phase 1/2 Recruiting

Brain Neoplasms, Lung Neoplasms

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04774718 2026-04-06

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1/2 Recruiting

Central Nervous System Neoplasms

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

Glioblastoma

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Phase 1/2 Terminated

5 enrolled 8 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

NCT01801111 2018-11-02

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Phase 1/2 Completed

138 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT01871805 2018-08-21

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

134 enrolled 35 charts

Carcinoma, Non-Small-Cell Lung